Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can hormone therapy spare fertility in a challenging endometrial cancer?

NCT ID NCT06468215

NEW Recruiting now Disease control Sponsor: Peking University People's Hospital Source: ClinicalTrials.gov ↗

First seen Aug 18, 2026 · Last updated Aug 18, 2026

Summary

This trial is testing two hormone-based approaches to treat early-stage, grade 2 endometrial cancer in women under 45 who wish to preserve their fertility. One approach uses a daily oral progesterone pill, while the other combines the pill with a hormone-releasing intrauterine device (Mirena IUD). The goal is to see which regimen leads to complete remission of the cancer faster and with a lower chance of recurrence, offering a potential alternative to hysterectomy for these patients.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Progesterone therapy (medroxyprogesterone acetate or megestrol acetate) alone or combined with a levonorgestrel intrauterine system (Mirena IUD)
What this could lead to
If successful, this could establish a standard fertility-sparing treatment for grade 2 endometrial cancer, allowing young women to preserve their fertility while effectively managing the disease.
What could go wrong
This is a small, early-phase trial with only 16 participants, so results may not be conclusive. The treatment may not achieve complete remission in all cases, and there is a risk of recurrence or progression, which could require more aggressive surgery.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CARCINOMA, ENDOMETRIOID are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Carcinoma, Endometrioid endometrial endometrioid adenocarcinoma endometrioid adenocarcinoma endometrium neoplasm follicular lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CARCINOMA, ENDOMETRIOID FERTILITY PRESERVATION

Contacts and locations

Locations

  • Peking University People's Hospital

    RECRUITING

    Beijing, Beijing Municipality, 100044, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.